Antibacterial agents act against bacterial infection either by killing the bacterium or by arresting its growth. They do this by targeting bacterial DNA and its associated processes, attacking bacterial metabolic processes including protein synthesis, or interfering with bacterial cell wall synthesis and function. Antibacterial Agents is an essential guide to this important class of chemotherapeutic drugs. Compounds are organised according to their target, which helps the reader understand the mechanism of action of these drugs and how resistance can arise. The book uses an integrated "lab-to-clinic" approach which covers drug discovery, source or synthesis, mode of action, mechanisms of resistance, clinical aspects (including links to current guidelines, significant drug interactions, cautions and contraindications), prodrugs and future improvements. Agents covered include: *agents targeting DNA - quinolone, rifamycin, and nitroimidazole antibacterial agents *agents targeting metabolic processes - sulfonamide antibacterial agents and trimethoprim *agents targeting protein synthesis - aminoglycoside, macrolide and tetracycline antibiotics, chloramphenicol, and oxazolidinones *agents targeting cell wall synthesis - beta-Lactam and glycopeptide antibiotics, cycloserine, isonaizid, and daptomycin Antibacterial Agents will find a place on the bookshelves of students of pharmacy, pharmacology, pharmaceutical sciences, drug design/discovery, and medicinal chemistry, and as a bench reference for pharmacists and pharmaceutical researchers in academia and industry.
| ISBN | 0470972440 | | Pages | 378 | | ISBN13 | 9780470972441
(What's this?) | | Weight (grammes) | 982 | | Publisher | John Wiley and Sons Ltd | | Published in | Chicester | | Imprint | Wiley-Blackwell (an imprint of John Wiley & Sons Ltd) | | Height (mm) | 256 | | Format | Hardback | | Width (mm) | 195 | | Publication date | 22 Jun 2012 | | Spine width (mm) | 22 | | DEWEY | 615.329 | | Academic level | Undergraduate, Postgraduate, Professional / Scholarly | | DEWEY edition | DC23 | |
|
|
|
Preface xi SECTION 1 INTRODUCTION TO MICROORGANISMS AND ANTIBACTERIAL CHEMOTHERAPY 1 1.1 Microorganisms 3 Key points 3 1.1.1 Classification 3 1.1.2 Structure 4 1.1.3 Bacterial detection and identification 17 1.1.4 Other than its mode of action, what factors determine the antibacterial activity of a drug? 25 1.1.5 Bacterial resistance 27 1.1.6 The 'post-antibiotic age'? 29 References 31 Questions 33 SECTION 2 AGENTS TARGETING DNA 35 2.1 Quinolone antibacterial agents 37 Key points 37 2.1.1 Discovery 37 2.1.2 Synthesis 39 2.1.3 Bioavailability 41 2.1.4 Mode of action and selectivity 44 2.1.5 Bacterial resistance 45 2.1.6 Clinical applications 47 2.1.7 Adverse drug reactions 50 2.1.8 Drug interactions 55 2.1.9 Recent developments 56 References 60 2.2 Rifamycin antibacterial agents 63 Key points 63 2.2.1 Discovery 63 2.2.2 Synthesis 65 2.2.3 Bioavailability 68 2.2.4 Mode of action and selectivity 69 2.2.5 Bacterial resistance 71 2.2.6 Clinical applications 71 2.2.7 Adverse drug reactions 77 2.2.8 Drug interactions 78 2.2.9 Recent developments 81 References 81 2.3 Nitroimidazole antibacterial agents 85 Key points 85 2.3.1 Discovery 85 2.3.2 Synthesis 86 2.3.3 Bioavailability 86 2.3.4 Mode of action and selectivity 87 2.3.5 Mechanisms of resistance 89 2.3.6 Clinical applications 90 2.3.7 Adverse drug reactions and contraindications 94 2.3.8 Drug interactions 95 2.3.9 Recent developments 97 References 97 Questions 101 SECTION 3 AGENTS TARGETING METABOLIC PROCESSES 103 3.1 Sulfonamide antibacterial agents 105 Key points 105 3.1.1 Discovery 105 3.1.2 Synthesis 107 3.1.3 Bioavailability 108 3.1.4 Mode of action and selectivity 111 3.1.5 Bacterial resistance 114 3.1.6 Clinical applications 115 3.1.7 Adverse drug reactions 119 3.1.8 Drug interactions 122 3.1.9 Recent developments 123 References 124 3.2 Trimethoprim 127 Key points 127 3.2.1 Discovery 127 3.2.2 Synthesis 128 3.2.3 Bioavailability 130 3.2.4 Mode of action and selectivity 130 3.2.5 Bacterial resistance 136 3.2.6 Clinical applications 136 3.2.7 Adverse drug reactions 138 3.2.8 Drug interactions 138 3.2.9 Recent developments 139 References 140 Questions 145 SECTION 4 AGENTS TARGETING PROTEIN SYNTHESIS 147 4.1 Aminoglycoside antibiotics 149 Key points 149 4.1.1 Discovery 149 4.1.2 Synthesis 152 4.1.3 Bioavailability 156 4.1.4 Mode of action and selectivity 158 4.1.5 Bacterial resistance 160 4.1.6 Clinical applications 161 4.1.7 Adverse drug reactions 165 4.1.8 Drug interactions 167 4.1.9 Recent developments 168 References 168 4.2 Macrolide antibiotics 173 Key points 173 4.2.1 Discovery 173 4.2.2 Synthesis 175 4.2.3 Bioavailability 177 4.2.4 Mode of action and selectivity 180 4.2.5 Bacterial resistance 181 4.2.6 Clinical applications 182 4.2.7 Adverse drug reactions 187 4.2.8 Drug interactions 189 4.2.9 Recent developments 192 References 193 4.3 Tetracycline antibiotics 197 Key points 197 4.3.1 Discovery 197 4.3.2 Synthesis 200 4.3.3 Bioavailability (agwuh and macgowan, 2006) 205 4.3.4 Mode of action and selectivity 210 4.3.5 Bacterial resistance 213 4.3.6 Clinical applications 217 4.3.7 Adverse drug reactions 223 4.3.8 Drug interactions 224 4.3.9 Recent developments 224 References 225 4.4 Chloramphenicol 231 Key points 231 4.4.1 Discovery 231 4.4.2 Synthesis 231 4.4.3 Bioavailability 232 4.4.4 Mode of action and selectivity 235 4.4.5 Bacterial resistance 235 4.4.6 Clinical applications 236 4.4.7 Adverse drug reactions 238 4.4.8 Drug interactions 239 4.4.9 Recent developments 239 References 241 4.5 Oxazolidinones 243 Key points 243 4.5.1 Discovery 243 4.5.2 Synthesis 245 4.5.3 Bioavailability 247 4.5.4 Mode of action and selectivity 248 4.5.5 Bacterial resistance 249 4.5.6 Clinical applications 251 4.5.7 Adverse drug reactions 252 4.5.8 Drug interactions 253 4.5.9 Recent developments 254 References 254 Questions 259 SECTION 5 AGENTS TARGETING CELL-WALL SYNTHESIS 261 5.1 b-lactam antibiotics 263 Key points 263 5.1.1 Discovery 263 5.1.2 Synthesis 272 5.1.3 Bioavailability 277 5.1.4
Enlarge
